318
Views
0
CrossRef citations to date
0
Altmetric
Correction

Correction

This article refers to:
Use of the incremental cost-effectiveness ratio for decision-making policies—what is the problem? A perspective paper

Article title: Use of the incremental cost-effectiveness ratio for decision-making policies—what is the problem? A perspective paper

Authors: Brougham, M., Schlander, M., Telser, H., Bakshi, S., & Sola-Morales, O.

Journal: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: http://doi.org/10.1080/14737167.2022.2064847

The Article Highlights section was incorrect in the published PDF. It has now been corrected with the below Article Highlights section.

Article Highlights

• Reimbursement decisions that spark public controversy, as seen in past NICE decisions to reject a range of effective but expensive treatments for rare diseases, are potential signals that the processes used to reach such decisions do not reflect the wider social welfare objectives of society.

• This notion is supported by recent higher-than-expected estimates of societal WTP for treatments for rare childhood dementias in the UK.

• QALY based ICER decision making systems have a number of known weaknesses, particularly in accounting for observed societal preferences (who benefits, the type of benefit, a “fair chance” – to coin short-hand names for but three), to the extent that extra-welfare characteristics are often either ignored or considered in an unsystematic and inconsistent fashion.

• At times, attempts have been made to address these weaknesses – such as through the provision of multiple ICER thresholds in the case of NICE’s Highly Specialised Technology (HST) evaluations for ultra-rare diseases albeit these thresholds appear particularly arbitrary in light of the Office of Health Economics £20k equivalence estimate of £900k for ultra-orphan diseases.

• Nevertheless, in the absence of substantive scope for discretion within existing processes, we suggest there are a range of alternative means (including MCDA and Cost-Benefit Analysis based on WTP measures) by which to mitigate these known weaknesses.

• HTA bodies considering process evolution should consider these approaches, already widely utilised outside of the healthcare system, as they have the potential to result in more comprehensive, systematic and accountable decision making.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.